Effectiveness of fremanezumab treatment in patients with migraine headache.

IF 2.9 3区医学 Q1 ANESTHESIOLOGY

Pain Medicine Pub Date : 2024-11-01 DOI:10.1093/pm/pnae050

Shoji Kikui, Danno Daisuke, Junichi Miyahara, Hanako Sugiyama, Kuniko Ota, Kenji Murakata, Yoshihiro Kashiwaya, Takao Takeshima

{"title":"Effectiveness of fremanezumab treatment in patients with migraine headache.","authors":"Shoji Kikui, Danno Daisuke, Junichi Miyahara, Hanako Sugiyama, Kuniko Ota, Kenji Murakata, Yoshihiro Kashiwaya, Takao Takeshima","doi":"10.1093/pm/pnae050","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy and safety of fremanezumab for migraine prevention.Design: Retrospective, single-center, real-world study.Setting: Regional tertiary headache center in Japan.Subjects: Adult individuals with migraine (n = 165, male = 17, female = 148; average age = 45.5 ± 16.0 years) who received fremanezumab between September 2021 and August 2022.Methods: Fremanezumab was administered subcutaneously at a monthly dose of 225 mg or quarterly dose of 675 mg based on patient preferences. Patients received fremanezumab treatment for up to 1 year unless it was discontinued. Monthly data were collected on migraine days, headache days, and days requiring acute medication.Results: Of the 165 patients, 125 (75.7%) received fremanezumab as their first anti-calcitonin gene-related peptide-related antibody drug. Significant reductions in monthly migraine days, headache days, and days requiring acute medication were observed in those with episodic and chronic migraines. The baseline monthly headache days was 8.1 ± 4.0 in the episodic migraine group, which reduced to 6.1 ± 4.8, 5.8 ± 4.4, 4.7 ± 3.6, and 4.6 ± 3.3 days at 1, 3, 6, and 12 months, respectively; in the chronic migraine group, the baseline monthly headache days was 20.9 ± 6.1, which reduced to 17.0 ± 8.9, 15.0 ± 9.2, 13.0 ± 7.7, and 12.0 ± 9.1 days at 1, 3, 6, and 12 months, respectively. Treatment benefits were enhanced after 6 months of administering fremanezumab in the chronic migraine group.Conclusions: In this real-world study of patients with migraine, fremanezumab appears to be effective and safe. Further studies are required to identify additional predictors of treatment success and failure with fremanezumab.","PeriodicalId":19744,"journal":{"name":"Pain Medicine","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/pm/pnae050","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy and safety of fremanezumab for migraine prevention.

Design: Retrospective, single-center, real-world study.

Setting: Regional tertiary headache center in Japan.

Subjects: Adult individuals with migraine (n = 165, male = 17, female = 148; average age = 45.5 ± 16.0 years) who received fremanezumab between September 2021 and August 2022.

Methods: Fremanezumab was administered subcutaneously at a monthly dose of 225 mg or quarterly dose of 675 mg based on patient preferences. Patients received fremanezumab treatment for up to 1 year unless it was discontinued. Monthly data were collected on migraine days, headache days, and days requiring acute medication.

Results: Of the 165 patients, 125 (75.7%) received fremanezumab as their first anti-calcitonin gene-related peptide-related antibody drug. Significant reductions in monthly migraine days, headache days, and days requiring acute medication were observed in those with episodic and chronic migraines. The baseline monthly headache days was 8.1 ± 4.0 in the episodic migraine group, which reduced to 6.1 ± 4.8, 5.8 ± 4.4, 4.7 ± 3.6, and 4.6 ± 3.3 days at 1, 3, 6, and 12 months, respectively; in the chronic migraine group, the baseline monthly headache days was 20.9 ± 6.1, which reduced to 17.0 ± 8.9, 15.0 ± 9.2, 13.0 ± 7.7, and 12.0 ± 9.1 days at 1, 3, 6, and 12 months, respectively. Treatment benefits were enhanced after 6 months of administering fremanezumab in the chronic migraine group.

Conclusions: In this real-world study of patients with migraine, fremanezumab appears to be effective and safe. Further studies are required to identify additional predictors of treatment success and failure with fremanezumab.

查看原文本刊更多论文

治疗偏头痛患者的氟马尼单抗疗效。

目的评估氟马尼珠单抗预防偏头痛的有效性和安全性：回顾性、单中心、真实世界研究：受试者：患有偏头痛的成年患者（n = 16，女性 = 1）：成年偏头痛患者（n = 165，男性 = 17，女性 = 148；平均年龄 = 45.5 ± 16.0 岁），在 2021 年 9 月至 2022 年 8 月期间接受了氟马尼珠单抗治疗：根据患者的偏好，每月皮下注射225毫克或每季度皮下注射675毫克的fremanezumab。除非停药，否则患者将接受长达1年的fremanezumab治疗。每月收集偏头痛天数、头痛天数和需要急性药物治疗天数的数据：结果：在165名患者中，125人（75.7%）接受了fremanezumab作为其首个抗降钙素基因相关肽抗体药物。观察发现，发作性偏头痛和慢性偏头痛患者的每月偏头痛天数、头痛天数和需要急性药物治疗的天数显著减少。发作性偏头痛组的基线月头痛天数为 8.1 ± 4.0 天，1、3、6 个月后分别减少到 6.1 ± 4.8 天、5.8 ± 4.4 天、4.7 ± 3.6 天和 4.6 ± 3 天。3天；慢性偏头痛组的基线月头痛天数为20.9±6.1天，在1、3、6和12个月时分别降至17.0±8.9天、15.0±9.2天、13.0±7.7天和12.0±9.1天。慢性偏头痛组在使用氟马尼珠单抗6个月后，治疗效果更佳：在这项针对偏头痛患者的真实世界研究中，fremanezumab 似乎既有效又安全。结论：在这项偏头痛患者的真实世界研究中，fremanezumab似乎有效且安全，但还需要进一步研究，以确定更多预测fremanezumab治疗成功和失败的因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pain Medicine 医学-医学：内科

CiteScore

6.50

自引率

3.20%

发文量

187

审稿时长

3 months

期刊介绍： Pain Medicine is a multi-disciplinary journal dedicated to pain clinicians, educators and researchers with an interest in pain from various medical specialties such as pain medicine, anaesthesiology, family practice, internal medicine, neurology, neurological surgery, orthopaedic spine surgery, psychiatry, and rehabilitation medicine as well as related health disciplines such as psychology, neuroscience, nursing, nurse practitioner, physical therapy, and integrative health.